{"id":11180,"date":"2024-10-19T09:42:14","date_gmt":"2024-10-19T01:42:14","guid":{"rendered":"http:\/\/www.mediazone.com.hk\/hkmvc\/?p=11180"},"modified":"2024-12-20T10:25:10","modified_gmt":"2024-12-20T02:25:10","slug":"revolutionizing-eye-care-treatment-with-quality-innovation","status":"publish","type":"post","link":"https:\/\/www.mediazone.com.hk\/hkmvc\/2024\/10\/19\/revolutionizing-eye-care-treatment-with-quality-innovation\/","title":{"rendered":"Revolutionizing eye care treatment with quality & innovation!"},"content":{"rendered":"

In the realm of ophthalmology, where precision and innovation are paramount, one company stands out for its commitment to excellence and dedication to improving visual health worldwide. Zhaoke Ophthalmology Limited (SEHK: 6622), founded in 2017 and listed on the Main Board of the Hong Kong Stock Exchange in April 2021, has swiftly become a leading player in the ophthalmic pharmaceutical industry.<\/h3>\n
\n

At the core of Zhaoke Ophthalmology’s mission is the relentless pursuit of research and development to address unmet medical needs in the field of eye care. With a robust portfolio of innovative and generic treatments, the company covers a wide range of solutions to treat major eye diseases affecting both the front and back of the eye.<\/p>\n

\"\"<\/a>

Dr. Benjamin Li, Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology<\/p><\/div>\n

\u201cWe are currently focused on major near-term development programs for drugs addressing five major ophthalmic diseaseswith huge unmet needs in China, namely dry eye disease, myopia, age-related macular degeneration, presbyopia and cornea epithelial defects,\u201d says Dr. Benjamin Li, Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology.\u00a0 \u201cThese include drugs like CsA and NVK002 which are in the New Drug Application stage, TAB014which are in the preparation stage for the New Drug Application stage, as well as Brimochol and ZKY001 which are in preparation for the pivotal Phase III clinical trial stage.\u201d
\nThe drug candidates of Zhaoke Ophthalmology strategically focus on major late-stage programs emphasizing the largestophthalmic indications. For example, over 163 million children in China currently suffer from myopia.\u00a0 If left untreated, it can lead to other, more complicated eye diseases \u2013 and the time window for intervention is narrow.\u00a0Zhaoke Ophthalmology\u2019s drug candidate NVK002 is potentially the second to market in China as a premium brand and imported product for treating myopia progression in children. The company conducted 2 Phase III trials for the drug and successfully concluded the one-year trial Mini-CHAMP in August 2023. The company is currently accelerating its regulatory approval in China, eager to do its part to offer a safe, effective and convenient solution to these patients and their families as soon as possible. \"\"<\/a><\/p>\n

One of the key pillars of Zhaoke Ophthalmology’s success is its state-of-the-art research, development and manufacturing facility in Nansha, Guangzhou, Guangdong Province, China. Designed and built in compliance with international cGMP requirements, the facility boasts cutting-edge equipment and machinery from leading global suppliers. With a focus on quality assurance and adherence to the highest industry standards, Zhaoke Ophthalmology’s facility ensures the production of safe, effective and high-quality ophthalmic drugs.\"\"<\/a>
\nIn addition to its manufacturing capabilities, the company prides itself on its strong research and development team. In fact, Zhaoke Ophthalmology is at the forefront of ophthalmic drug discovery and development, having specialized expertise and a track record of developing novel formulations for innovative drugs. The company\u2019s continued investment into its chemistry, manufacturing, and control (CMC) laboratories, as well as its pharmacology laboratories, position itself as a leader in the ophthalmic research field.<\/p>\n

\"\"<\/a>Strategic partnerships play a critical role in Zhaoke Ophthalmology’s growth strategy. By collaborating with domestic and international pharmaceutical firms, the company aims to expand its global reach and establish itself as a key player in the ophthalmology market. \u201cThe distribution agreement we recently signed for Bimatoprost Timolol in Malaysia is a good example of how we are expanding our commercialization activities at Zhaoke Ophthalmology. This generic fixed-dose combination drug, developed by our company for the treatment of glaucoma, is already gaining popularity in the Chinese market and is now set to reach patients in Malaysia through a partnership with the leading local pharma company Pharmaniaga. This strategic collaboration is an example of our dedication to making ophthalmic treatments more accessible to those in need,\u201d explains Dr. Li.<\/p>\n

In conclusion, Zhaoke Ophthalmology’s unwavering dedication to innovation, excellence and collaboration has positioned it as a pioneering force in the field of ophthalmic pharmaceuticals. With a focus on research and development, state-of-the-art manufacturing capabilities and strategic partnerships, Zhaoke Ophthalmology is poised to make a lasting impact on the global landscape of eye care. As the company continues on its path to becoming a global leader in ophthalmology, the future of visual health looks brighter than ever.
\nThe Mediazone Group congratulates Zhaoke Ophthalmology Limited for winning the Hong Kong\u2019s Most Valuable Companies 2025 Award. We look forward to seeing the company\u2019s continued growth and what more it will contribute to the eyecare industry globally.
\nFor more information see the video below or visit www.zkoph.com<\/a><\/p>\n